SELLAS Life Sciences Group (SLS) Study Update summary
Event summary combining transcript, slides, and related documents.
Study Update summary
11 Jan, 2026Study milestone and context
The pivotal phase III REGAL study for GPS in AML patients in complete remission after second-line salvage therapy reached the interim analysis trigger of 60 events.
REGAL is an open-label, event-driven, registrational Phase 3 trial with overall survival as the primary endpoint and 126 patients enrolled.
Interim analysis represents 48% of the study population; final analysis will occur at 80 events (63%).
A conservative O'Brien-Fleming boundary will be used to determine statistical significance at interim and final analyses.
A webcast was scheduled to discuss the process and potential outcomes of the interim analysis.
IDMC process and possible outcomes
The IDMC will review efficacy, futility, and safety data at a meeting scheduled for January 2025, using unblinded data.
The IDMC will hold closed and open sessions to review unblinded and blinded data, respectively, and provide recommendations.
Recommendations may include continuing the trial, modifying it, or discontinuing based on efficacy or futility; discontinuation could result from either futility or exceptional efficacy observed at interim analysis.
If the trial proceeds to 80 events, it may indicate GPS extends survival and is a positive sign.
Any recommendation to stop for efficacy will be communicated to the FDA before public disclosure.
Study design and objectives
IDMC is responsible for periodic reviews of safety, efficacy, and futility, ensuring scientific and clinical validity.
Latest events from SELLAS Life Sciences Group
- GPS met REGAL’s OS endpoint as SLS009 advances across AML settings.SLS
Corporate presentation - GPS advances in Phase 3 AML as SLS009 delivers promising Phase 2 results.SLS
Corporate presentation - REGAL: GPS cut death risk 41% and extended median OS to 24.0 months.SLS
Study result - REGAL topline results are expected in November as SLS009 advances, with $134.7 million in cash.SLS
Q3 2026 - Net loss rose to $18.0M in H1 2026; cash reached $138.3M as clinical programs advanced.SLS
Q2 2026 - All proposals passed amid strong financial growth and clinical progress toward pivotal milestones.SLS
AGM 2026 - Pivotal AML trial data for GPS and phase II results for SLS009 are expected to drive major milestones.SLS
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Pivotal data for GPS and SLS-009 in AML expected by year-end, backed by strong financials.SLS
A.G.P.'s Annual Virtual Healthcare Conference - Imminent phase III and II data for GPS and SLS009 in AML signal major near-term catalysts.SLS
Stifel 2026 Targeted Oncology Virtual Forum - GPS and SLS009 advance as late-stage, first-in-class AML therapies with pivotal data imminent.SLS
R&D Day 2025